Compare DexCom, Inc. (DXCM) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? DexCom, Inc. trades at $90.65 (market cap $33.79B), while Rex Fang & Innovation Equity Premium Income ETF trades at $42.03. The key difference: DexCom, Inc. is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | FEPI | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.80 | $49.54 |
52-Week Low | $54.84 | $37.98 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FEPI trades at $41.80, showing slight daily weakness with a 0.17% decline. The ETF maintains a bullish technical signal with strong moving average support and weekly dividend distributions averaging $0.20-0.21. Recent news highlights FEPI's aggressive covered call strategy targeting AI and mega-cap tech names to generate its 25% yield, though analysts caution about NAV erosion risks during market downturns.
The outlook remains cautiously optimistic given the bullish technical setup and high income generation, but investors face significant risk from the concentrated tech portfolio and covered call strategy that limits upside potential. Market sentiment is divided between yield-seeking investors and those concerned about long-term NAV preservation in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
